Single-Cell RNA Sequencing (scRNA-seq) in Cardiac Tissue: Applications and Limitations
Mingqiang Wang,Mingxia Gu,Ling Liu,Yu Liu,Lei Tian
DOI: https://doi.org/10.2147/VHRM.S288090
2021-10-03
Vascular Health and Risk Management
Abstract:Mingqiang Wang, 1 Mingxia Gu, 2, 3 Ling Liu, 4 Yu Liu, 1 Lei Tian 1 1 Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA; 2 Perinatal Institute, Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA; 3 Center for Stem Cell and Organoid Medicine, CuSTOM, Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA; 4 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, 94305, USA Correspondence: Mingqiang Wang; Lei Tian Stanford University School of Medicine, Stanford Cardiovascular Institute, 1291 Welch Road, Biomedical Innovations Building, Stanford, CA, 94305-5454, USA Tel +1 650 723-5386 Fax +1 650 736-7925 Email ; Cardiovascular diseases (CVDs) are a group of disorders of the blood vessels and heart, which are considered as the leading causes of death worldwide. The pathology of CVDs could be related to the functional abnormalities of multiple cell types in the heart. Single-cell RNA sequencing (scRNA-seq) technology is a powerful method for characterizing individual cells and elucidating the molecular mechanisms by providing a high resolution of transcriptomic changes at the single-cell level. Specifically, scRNA-seq has provided novel insights into CVDs by identifying rare cardiac cell types, inferring the trajectory tree, estimating RNA velocity, elucidating the cell–cell communication, and comparing healthy and pathological heart samples. In this review, we summarize the different scRNA-seq platforms and published single-cell datasets in the cardiovascular field, and describe the utilities and limitations of this technology. Lastly, we discuss the future perspective of the application of scRNA-seq technology into cardiovascular research. Keywords: cardiovascular diseases, clustering, trajectory inference, RNA velocity, cell–cell communication, spatial genomics Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million (32.1%) lives in 2015, up from 12.3 million (25.8%) in 1990. 1,2 CVDs are highly heterogeneous diseases involving a group of disorders of the heart and blood vessels, which include cardiomyopathy, hypertensive heart disease, heart failure, coronary artery disease, cerebrovascular disease, rheumatic heart disease and others. 3 CVDs are complex in nature, stemming from molecular alternations at the genetic, epigenetic, transcriptomic, and even proteomic levels in various cardiac cell types. 4,5 Accurate elucidation of cellular heterogeneities is necessary for decoding the pathogenic mechanisms of CVDs, identifying novel therapeutic targets, and developing effective treatment strategies. 6 The profiling of cellular heterogeneity at the transcriptomic level in cardiac tissues has been considered as a promising direction for measuring the global transcriptional activity dynamics, which underlie the phenotypic diversity of multiple cardiac cell types. 7,8 Over the years, next-generation sequencing (NGS) technologies have led to many discoveries in biomedical sciences, including the phenotypic consequences of molecular variation in cardiovascular research. 9–11 Until recently, bulk RNA sequencing (RNA-seq) had been primarily used to profile the averaged gene expression from tissues that consist of various cell types. 12 Bulk profiling hence ignores the stochasticity of gene expression in each cell type and indicates average values from the heterogeneous population of cells, which are affected by the relative cell-type abundance and the states of each cell type within a sequencing sample. 13 Molecular differences at the transcriptional level between distinct sub-cell types are also missing. In order to measure the transcriptome of each cell, several high-throughput single-cell RNA-sequencing (scRNA-seq) technologies have been developed and commercialized (Table 1). 14–24 scRNA-seq enables the characterization and identification of transcriptionally different subpopulations at the single-cell level. This approach has the potential to identify novel directions to develop therapeutic strategies. 25 Table 1 scRNA-Seq Sequencing Methods Comparison The number of scRNA-seq studies in cardiovascular research has rapidly increased in recent years. A recent search with the keyword "(scRNA-seq or single-cell transcript*)[TIAB] AND (heart or cardiac or cardio*)[TIAB] in NCBI's PubMed database of scientific publications returned 1238 articles (Sept. 5, 2021), 257 of which were published in 2020 and 254 of which published in 202 -Abstract Truncated-